Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21315421 | 0.92 | KCNH2 (0.36) | KCNH2 | |
| SCHEMBL565416 | 0.86 | — | — | |
| SCHEMBL5563689 | 0.85 | — | — | |
| SCHEMBL17368831 | 0.84 | CYP11B1 (0.33) | CYP11B1CYP11B2KCNH2 | |
| SCHEMBL126686 | 0.80 | — | — | |
| SCHEMBL127016 | 0.80 | — | — | |
| SCHEMBL126707 | 0.80 | — | — | |
| SCHEMBL3505574 | 0.77 | KCNH2 (0.33) | CYP11B1CYP11B2KCNH2 | |
| SCHEMBL320777 | 0.77 | KCNH2 (0.33) | CYP11B1CYP11B2KCNH2 | |
| SCHEMBL1811309 | 0.77 | KCNH2 (0.33) | CYP11B1CYP11B2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376422-B2 | Dihidropyridin-2-one benzamine compounds | Epizyme, Inc. (US) | 2016-06-28 | — | — | US | claimed |
| EP-2697198-B1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2016-06-08 | — | — | EP | claimed |
| EP-2697198-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2014-02-19 | — | — | EP | claimed |
| EP-2373649-B1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2013-01-23 | — | — | EP | claimed |
| WO-2012142513-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2012-10-18 | — | — | WO | claimed |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Janssen Pharmaceuticals, Inc. | 2012-02-09 | — | — | US | claimed |
| EP-2373649-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| EP-2280965-A1 | THIAZOL-4-CARBOXYLIC ACID ESTERS AND THIOESTERS AS PLANT PROTECTION AGENTS | BAYER CROPSCIENCE AG (DE) | 2011-02-09 | — | — | EP | claimed |
| WO-2010060589-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | claimed |
| WO-2009132785-A1 | THIAZOL-4-CARBOXYLIC ACID ESTERS AND THIOESTERS AS PLANT PROTECTION AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT | 2009-11-05 | — | — | WO | claimed |
| EP-1776349-A2 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-25 | — | — | EP | claimed |
| WO-2006017836-A2 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-02-16 | — | — | WO | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-11725008-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230027126-A1 | ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-01-26 | — | — | US | disclosed |
| EP-3856188-A1 | AMINOPYRIMIDINE COMPOUND | Cardurion Pharmaceuticals, LLC (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2006063805-A1 | 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES | BAYER SCHERING PHARMA AKTINGESELLSCHAFT (DE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006024932-A1 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF B-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006017844-A1 | NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006017836-A2 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11725008-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | PRMT1, PRMT5, PRMT3 | CYP11B1 2266/4885CYP11B2 2555/4885KCNH2 4091/4885 |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM2, GRM5, GRIA2 | CYP11B1 2168/4885CYP11B2 1188/4885KCNH2 1299/4885 |
| US-20230027126-A1 | ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES | PRMT1, PRMT5, PRMT3 | CYP11B1 2266/4885CYP11B2 2555/4885KCNH2 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.